MSACL 2017 EU Abstract

Multimodal Molecular Profiling by Mass Spectrometry (Imaging): On its Way to Clinics?

Tiffany Porta (Presenter)
Maastricht University

Bio: Tiffany Porta received her PhD in 2013 in Pharmaceutical Sciences at the University of Geneva. She then moved to the Netherlands to work as a postdoctoral researcher at the FOM-AMOLF institute (Amsterdam) and the Maastricht University. Dr Porta was appointed as Assistant professor at the M4i institute in June 2016. Her main research is focused on translational research of MS (imaging) molecular-based techniques that are being developed to improve the accuracy of (cancer) diagnostics.

Authorship: Tiffany Porta (1), Pierre-Maxence Vaysse (1,2), Steven Olde Damink (2), Ron Heeren (1)
(1) Maastricht MuliModal Molecular Imaging (M4I) institute, Department of Imaging Mass Spectrometry, Maastricht University, Maastricht, NL; (2) Department of Surgery – NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, NL

Short Abstract

Tissue diagnostics can be challenging due to the presence of confounding factors such as inflammation or the lack of a minimum level of differentiation of tumor cells. Recently, histological evaluation of tumor based on tissue-specific molecular signature has revealed his potential to help accurate tissue diagnosis. Here, we highlight the MS-based tissue classification techniques of tomorrow that would help clinicians with their daily practice. Namely, in the hands of surgeons, rapid evaporative ionization mass spectrometry would guide in real-time and optimize surgical resection within the anatomic boundaries reducing the incidence of incomplete tumor resection. The pathologists could greatly benefit from laser microdissection coupled to mass spectrometry to improve their diagnostics from frozen sections in a minute.

Long Abstract




Conclusions & Discussion

References & Acknowledgements:

This work has been made possible with the support of the Dutch Province of Limburg.

Financial Disclosure

Board Memberno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above: